Seoulin Bioscience Co.,Ltd.
KKRX:0380703,675.00
KRW
-95.00
(-2.52%)
ISIN
KR7038070009
Return %
Stock
S&P 500
1Y
-42.68
14.39
3Y
-50.30
81.42
5Y
-82.00
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 110
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seongnam-si South Korea
- IPO Date
- Oct 25, 2005
- Website
- seoulin.co.kr
- Similar Companies
- Business
- Seoulin Bioscience Co.,Ltd. is a South Korea-based bio-infrastructure and healthcare solutions provider specializing in the development, manufacture, and distribution of life science research tools, eco-friendly sanitation systems, molecular diagnostics, and medical aesthetic equipment. Founded in 1984 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company caters to academic institutions, biopharmaceutical manufacturers, clinical laboratories, healthcare facilities, and industrial enterprises domestically and internationally. Seoulin Bioscience operates across three primary business divisions: Bio-Infrastructure, Eco-Bio Environmental Solutions, and Healthcare and Medical Devices. The company's product and service portfolio comprises: life science reagents, cell culture media, molecular biology consumables, bioprocessing materials, and advanced analytical instrumentation supplied in partnership with global biotechnology vendors; custom oligonucleotide synthesis, genomic sequencing, and bio-analytical contract research services; eco-friendly sanitization systems marketed under the ecoTree brand, including the ecoTree-M and ecoTree-L slightly acidic hypochlorous acid (HOCl) water generators for medical, agricultural, and industrial pathogen control; molecular diagnostic platforms and microRNA-based early detection assay kits marketed under the miQ brand for neurological disorders, dementia, and maternal health conditions; and specialized medical aesthetic technologies, encompassing plasma-based skin treatment devices, radiofrequency aesthetic systems, and motorized micro-grafting medical perforation devices including the STALUKE system. In recent strategic developments, Seoulin Bioscience has accelerated its transition from a specialized bio-distribution business toward a vertically integrated, manufacturing-oriented healthcare platform. The company expanded its medical device division by completing the acquisition of a 100 percent equity interest in medical aesthetics developer Staon Medical Co., Ltd. (formerly Seoulin Medicare), integrating in-house research, manufacturing, and global export channels. To rationalize its business structure, Seoulin Bioscience divested its full shareholding in fermented cosmetics subsidiary Genozyme Co., Ltd. On the product and commercial front, the company launched the ecoTree-L large-capacity on-site hypochlorous acid generator for industrial and institutional infection prevention, entered into a strategic memorandum of understanding with the Chungbuk Veterinary Medical Association to advance veterinary pathogen management, secured global service authorization from Revvity for specialized analytical systems, and received the Cytiva Best Collaboration Award for bioprocess distribution excellence.